Angelica Welch
Articles
Optimal Strategies Expand How Oncologists Target Treatment in NSCLC
November 29, 2018
Article
The acceptance of next-generation sequencing (NGS) platforms and cell-free DNA (cfDNA) have enabled oncologists to more specifically target genetic mutations in the treatment of patients with non–small cell lung cancer (NSCLC), according to Benjamin P. Levy, MD.
Trials Answer Questions About Duration of Treatment in HER2+ Breast Cancer
November 27, 2018
Article
The optimal duration of treatment for patients with HER2-positive breast cancer has been called into question by recent findings from the NSABP B-52, PERSEPHONE, and APT clinical trials.
FDA Grants Olaparib Priority Review for Frontline Maintenance in Ovarian Cancer
November 12, 2018
Article
The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for olaparib (Lynparza) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
Olaparib Significantly Improves PFS in Advanced BRCA+ Ovarian Cancer
November 06, 2018
Article
The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) as frontline maintenance therapy in women with BRCA-positive advanced ovarian cancer, according to findings reported at the 2018 European Society of Medical Oncology Congress.
FDA Advisory Committee Recommends Approval of Rituximab Biosimilar to Treat NHL
October 10, 2018
Article
The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended approval of CT-P10, a biosimilar for the monoclonal antibody rituximab (Rituxin), for 3 non-Hodgkin lymphoma indications in a 16-0 vote.
Asymptomatic, Young Patients With MCL May Avoid Active Treatment
September 25, 2018
Article
Frontline therapy may be able to be avoided in asymptomatic, young, fit patients with mantle cell lymphoma (MCL), explained Simon Rule, MD, PhD, in a presentation during the 2018 SOHO Annual Meeting. Active treatment in this patient population could potentially lead to unnecessary toxicities, he added.
Carfilzomib-Based Regimens Deemed Safe in Multiple Myeloma
September 21, 2018
Article
Two trials have shown that carfilzomib (Kyprolis)-based regimens appeared to be a safe and effective treatments for all patients with multiple myeloma, according to updated data from the ASPIRE and ENDEAVOR trials presented at the 2018 SOHO Annual Meeting.
Next-Generation Sequencing Found to Be Most Cost-Effective in Advanced NSCLC
June 06, 2018
Article
Next-generation sequencing (NGS) in metastatic non–small cell lung cancer (NSCLC) can save Center for Medicare and Medicaid Services (CMS) payers $1.4 million to $2.1 million.
Advances in HER2+ Breast Cancer
March 08, 2018
Article
A wave of novel treatments and FDA approvals has recently swept through the HER2-positive breast cancer space. Kimberly L. Blackwell, MD, oncologist at Duke Cancer Institute, discusses these recent advancements.
Adjuvant Treatment Options for HER2+ Breast Cancer Continue to Expand
November 29, 2017
Article
Although much success has been seen, 15% of patients with HER2-positive breast cancer will recur. Outcomes for those patients need to be improved, said Sara M. Tolaney, MD.